Shockwave C2+ Debut Joins Packed Shockwave Agenda at Transcatheter Cardiovascular Therapeutics Conference in San Francisco
SANTA CLARA, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the planned U.S. introduction of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter following approval by the U.S. Food and Drug Administration. The Shockwave C2+ catheter provides 50 percent more pulses per catheter than the Shockwave C2 catheter that was approved in the U.S. in 2021. The enhanced C2+ catheter will make its U.S. debut at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation, with the full commercial launch planned for the beginning of November.
"The enhancements of Shockwave C2+ will be an added benefit of IVL for optimally treating complex calcium, including more diffuse disease, as well as nodular and thick, eccentric calcium," said Richard Shlofmitz, MD, Chairman, Department of Cardiology, St. Francis Hospital in Roslyn, New York, who performed the first U.S. commercial case with Shockwave C2+. "When additional pulses are added to the existing intuitive catheter design and simple-to-use system that are foundational to the success of Shockwave IVL, the result is an updated catheter that can enhance workflow and improve procedural efficiency."
TCT23 to Feature New Coronary IVL Data and Insights and Symposia on COSIRA-II
The following scientific sessions and symposia supporting Shockwave Medical's growing portfolio of technologies and clinical studies will be taking place at TCT:
Monday, October 23, 2023
TCT WorldLink Latin America Featured Clinical Science: Complex Coronary Intervention | ||
Presentation Title: | Shock India Registry: Multicenter Registry of Coronary IVL in Calcified Coronary Arteries in Real-World Indian Patient Population | |
Time and Location: | 10:30 AM – 10:41 AM; Presentation Theater 3, Room 215, Level 2, Moscone South | |
Presenter: | Prof. Ashok Seth, MBBS*, Fortis Escorts Heart Institute & Research Centre |
Tuesday, October 24, 2023
Shockwave Medical Sponsored Symposia | ||
Presentation Title: | The COSIRA-II Trial: Designed To Demonstrate Refractory Angina Relief with the Coronary Sinus Reducer | |
Time and Location: | 2:00 PM – 3:00 PM, Presentation Theater 1, Room 205, Level 2, Moscone South | |
Presenters: | Gregg W. Stone, MD, Mount Sinai Heart Health System; Allen Jeremias, MD*, St. Francis Hospital; Timothy D. Henry, MD, The Christ Hospital; Prof. ... |